Imodium Instant

Loperamide Hydrochloride, the active ingredient in Imodium Instant, is an antidiarrheal presented as an oral tablet for oral use. It reduces the frequency of watery stools and is indicated for acute diarrhea, chronic diarrhea, and irritable bowel syndrome with diarrhea in adult patients.

GNH USA supplies Imodium Instant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Imodium Instant (loperamide) acts on the gastrointestinal tract to control excessive bowel movements associated with diarrheal disorders.

- Acute diarrhea: reduces stool frequency and improves consistency. - Chronic diarrhea: helps maintain regularity in long‑term diarrheal conditions. - Irritable bowel syndrome with diarrhea (IBS‑D): alleviates episodic diarrheal bouts and associated discomfort.

Loperamide may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Constipation - Abdominal cramps - Nausea - Dry mouth - Dizziness - Headache

Serious or Rare Side Effects: - Severe constipation leading to bowel obstruction - Toxic megacolon - Allergic reactions such as rash or angioedema - Cardiac arrhythmias (e.g., QT prolongation) - Ileus - Marked abdominal pain

Before using Imodium Instant, consider the following safety measures.

- Do not exceed the recommended dose: follow the prescriber's instructions. - Avoid use in bacterial enterocolitis: may worsen infection. - Use caution in hepatic impairment: reduced metabolism may increase exposure. - Avoid concomitant use with strong CYP3A4 inhibitors: risk of elevated plasma levels. - Store at room temperature: keep in the original pack, protect from moisture.

Loperamide can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Quinidine or other potent CYP3A4 inhibitors: may cause toxicity. - Other antidiarrheal agents (e.g., diphenoxylate): risk of excessive gut motility suppression. - Drugs that prolong the QT interval (e.g., macrolide antibiotics): increased cardiac risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers such as rifampin: may reduce efficacy. - Anticholinergic medications: may intensify dry‑mouth effects. - Opioid analgesics: additive central opioid activity. - Antifungal azoles (e.g., ketoconazole): may modestly raise loperamide levels.